Drug intelligence / Profile preview

ELN584105

Development stage: Preclinical
Lead developer: Prothena
Modality: Small Molecules

Overview

ELN584105 is a preclinical small molecule drug candidate that was initially part of Elan's early-stage neuroscience programs. Following the demerger of Elan's drug discovery business into Prothena Corporation, ELN584105 became part of Prothena's portfolio, which focuses on protein misfolding diseases. It is being developed for neurodegenerative diseases such as Parkinson's disease and multiple sclerosis.

Beyond the preview

Go deeper on ELN584105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELN584105.

Explore the full profile